#United States #Denver #Bausch Health #Salix #Liver Meeting

Bausch Health's Insights on Alcohol-Associated Hepatitis at The Liver Meeting 2026

Bausch Health Companies Inc., through its gastroenterology division, Salix Pharmaceuticals, is gearing up to present significant findings at The Liver Meeting® 2026, held from November 5-9 in Denver, Colorado. This annual event, organized by the American Association for the Study of Liver Diseases, brings together professionals and researchers to discuss advancements in liver disease management and treatment.

Focus on Severe Alcohol-Associated Hepatitis

The research titled "Clinical Burden and Outcomes in a Large Real-World Cohort of Patients Hospitalized with Severe Alcohol-Associated Hepatitis" sheds light on the grave realities faced by patients suffering from severe alcoholic hepatitis (AH). The study encompasses a substantial cohort of 1,630 adults hospitalized for this condition across the United States. The results reveal a stark picture: over a 12-month period, the overall survival rate for these patients was a concerning 62%, indicating a high mortality risk among individuals affected by this serious health issue.

Additionally, the findings noted that 31.4% of patients faced readmission within just 30 days post-discharge, a statistic that escalated to 69.1% within a year. Highlighting the critical situation even further, the study found that 8.5% of the patients required liver transplantation within the same timeframe.

The Importance of Real-World Evidence

Dr. Jonathan Sadeh, M.D., M.Sc., who serves as the Executive Vice President and Chief Medical Officer of Bausch Health, emphasized the importance of generating real-world evidence. He stated, “The findings of this study highlight the substantial burden of advanced liver disease and the urgent unmet need facing patients hospitalized with severe alcohol-associated hepatitis.” This statement reiterates the necessity for enhanced management strategies and innovative therapeutic approaches to combat severe AH, underscoring the need for ongoing research in this area.

A Call for Enhanced Strategies

The rising incidence of liver diseases associated with alcohol abuse presents a pressing challenge for healthcare providers. As more individuals find themselves diagnosed with advanced liver conditions, the demand for effective treatment methods increases significantly. The research presented at The Liver Meeting aims to pave the way for future studies that could lead to better management protocols and therapies for those struggling with alcohol-associated health issues.

Bausch Health’s commitment to improving outcomes for individuals affected by serious liver diseases remains steadfast. With Salix Pharmaceuticals being one of the largest specialty pharmaceutical businesses globally, their dedication to developing innovative solutions for gastrointestinal diseases is critical.

As this study unfolds at The Liver Meeting 2026, it brings hope for both medical professionals and patients seeking enhanced care options in the face of severe liver conditions.

For more information about Salix and their range of products focused on gastrointestinal health, visit Salix's website or connect with them on LinkedIn. For broader insights about Bausch Health, check out Bausch Health's official website.